Enovis Flourishes in First Year as Stand-Alone
Enovis reported 4Q22 orthopedic sales of $162.5 million, +10.4% compared to 4Q21. Including contributions from acquisitions, the company generated $599.4...
Enovis reported 4Q22 orthopedic sales of $162.5 million, +10.4% compared to 4Q21. Including contributions from acquisitions, the company generated $599.4...
The company's reported orthopedic sales grew by low-single digits during the third quarter of its 2023 fiscal year....
The company exited 2022 with mid-single digit growth despite macro headwinds, driven by its C360 portfolio and international sales....
The company exceeded $1 billion in annual sales for the first time in 2022, representing high-single digit growth compared to...
The company exited 2022 with early momentum in its plan to revitalize its orthopedics franchise and improve execution....
The company's organic orthopedic sales declined slightly in 2022 as a faulty software implementation hampered 4Q sales....
The company grew in the mid-single digits for 2022 when excluding the impact of foreign currency translation....
The company grew in the mid-single digits in 2022, driven by strong performances in joint replacement, trauma and sports medicine....
The company closed 2022 with a strong sales performance in the U.S. but endured COVID surges in China and...
The company's orthopedic sales grew in the mid-single-digits for FY 2Q23 on the strength of core spine and enabling technology...
Login
Register for a free account
As a guest member you get access to more articles and webinars every month.